These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25903343)

  • 21. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
    Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
    Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
    Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suitable fusion of N-terminal heptad repeats to achieve covalently stabilized potent N-peptide inhibitors of HIV-1 infection.
    Lai W; Wang C; Yan J; Liu H; Zhang W; Lin B; Xi Z
    Bioorg Med Chem; 2020 Feb; 28(4):115214. PubMed ID: 31932193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide.
    Ray N; Blackburn LA; Doms RW
    J Virol; 2009 Apr; 83(7):2989-95. PubMed ID: 19153234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
    Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
    J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
    Pan C; Cai L; Lu H; Qi Z; Jiang S
    J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.
    Montefiori DC; Filsinger Interrante MV; Bell BN; Rubio AA; Joyce JG; Shiver JW; LaBranche CC; Kim PS
    Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
    Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
    Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
    Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.
    Montgomery DL; Wang YJ; Hrin R; Luftig M; Su B; Miller MD; Wang F; Haytko P; Huang L; Vitelli S; Condra J; Liu X; Hampton R; Carfi A; Pessi A; Bianchi E; Joyce J; Lloyd C; Geleziunas R; Bramhill D; King VM; Finnefrock AC; Strohl W; An Z
    MAbs; 2009; 1(5):462-74. PubMed ID: 20065653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.
    Qi Z; Pan C; Lu H; Shui Y; Li L; Li X; Xu X; Liu S; Jiang S
    Biochem Biophys Res Commun; 2010 Jul; 398(3):506-12. PubMed ID: 20599765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
    Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
    Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
    [No Abstract]   [Full Text] [Related]  

  • 36. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
    Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
    AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.
    Pietzsch J; Scheid JF; Mouquet H; Seaman MS; Broder CC; Nussenzweig MC
    J Virol; 2010 May; 84(10):5032-42. PubMed ID: 20219932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.
    Bianchi E; Joyce JG; Miller MD; Finnefrock AC; Liang X; Finotto M; Ingallinella P; McKenna P; Citron M; Ottinger E; Hepler RW; Hrin R; Nahas D; Wu C; Montefiori D; Shiver JW; Pessi A; Kim PS
    Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10655-60. PubMed ID: 20483992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization.
    Huarte N; Lorizate M; Pérez-Payá E; Nieva JL
    Curr Top Med Chem; 2011 Dec; 11(24):2985-96. PubMed ID: 22044227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.